Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058617 · ClinicalTrials.gov registry record · Phase 1
Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
A Phase 1 study of Epstein-Barr Virus-Related Hodgkin Lymphoma and Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT00058617 is a Phase 1 study of Epstein-Barr Virus-Related Hodgkin Lymphoma and Epstein-Barr Virus-Related Non-Hodgkin Lymphoma that has completed, run by Baylor College of Medicine. The registered enrollment target is 13 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00058617, a Phase 1 study of Epstein-Barr Virus-Related Hodgkin Lymphoma and Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patients have a type of lymph gland cancer called Hodgkin or non-Hodgkin Lymphoma which has come back or not gone away after treatment, including the best treatment known for relapsed Lymphoma. Patients are being asked to volunteer to be in a research study using Epstein Barr virus specific cytotoxic T lymphocytes, a new experimental therapy. This therapy has never been used in patients with Hodgkin disease or this type of non-Hodgkin Lymphoma but it has been used successfully in children with other types of blood cancer caused by EBV after bone marrow transplantation. Some patients with Hodgkin or non-Hodgkin Lymphoma show evidence of infection with the virus that causes infectious mononucleosis Epstein Barr virus before or at the time of their diagnosis of the Lymphoma. EBV is often found in the cancer cells suggesting that it may play a role in causing Lymphoma. The cancer cells infected by EBV are very clever because they are able to hide from the body's immune system and escape destruction. Investigators want to see if it's possible to grow special white blood cells, called T cells, that have been trained to kill EBV infected cells. Purpose The purpose of this study is to find the largest safe dose of EBV specific cytotoxic T cells, to learn what the side effects are and to see whether this therapy might help patients with Hodgkin disease and non-Hodgkin Lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL Injection of EBV Specific CTLs
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1996-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058617
The ClinicalTrials.gov registry entry for NCT00058617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Epstein-Barr Virus-Related Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Injection of EBV Specific CTLs is the first listed.
NCT00058617 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00058617 about?
NCT00058617 is a clinical study titled "Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL". Patients have a type of lymph gland cancer called Hodgkin or non-Hodgkin Lymphoma which has come back or not gone away after treatment, including the best treatment known for relapsed Lymphoma. Patients are being asked to volunteer to be in a research study using Epstein Barr virus specific cytotox...
What is the current status of trial NCT00058617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 1996-01. Estimated completion is 2014-07.
What conditions does trial NCT00058617 study?
This clinical trial studies the following conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00058617?
The interventions under investigation include: Injection of EBV Specific CTLs (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058617?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00058617 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Epstein-Barr Virus-Related Hodgkin Lymphoma
All registered trials for this condition
Epstein-Barr Virus-Related Non-Hodgkin Lymphoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.